Global Glucagon Injection Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Glucagon Injection Market Research Report 2024
Glucagon is a metabolic hormone secreted by the pancreas that raises blood glucose levels by causing the liver to rapidly convert glycogen (the stored form of glucose) into glucose, which is then released into the bloodstream. Glucagon and insulin are two critical hormones in a glycemic control system that keeps blood glucose at the right level in healthy individual. Glucagon is a medicine which used to treat severe low blood sugar (hypoglycemia). Glucagon works by telling your body to release sugar (glucose) into the bloodstream to bring the blood sugar level back up.
According to Mr Accuracy reports’s new survey, global Glucagon Injection market is projected to reach US$ 870.2 million in 2029, increasing from US$ 575 million in 2022, with the CAGR of 6.1% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Glucagon Injection market research.
The Glucagon injection market is driven by the rising prevalence of diabetes and hypoglycemia, and the growing awareness of the importance of emergency treatment for severe low blood sugar episodes. Glucagon injections are life-saving emergency medications used to rapidly raise blood sugar levels in individuals experiencing severe hypoglycemia. The rise in the global diabetic population and the need for effective management of insulin-related conditions contribute to market growth as glucagon injections offer a crucial solution in emergency situations. Moreover, advancements in device design and the development of user-friendly glucagon delivery systems have improved the accessibility and ease of administration. However, the market also faces challenges, including the need for patient education on proper administration and storage of glucagon injections, and the complexity of the regulatory landscape for medical emergency medications. Additionally, addressing affordability and expanding access to glucagon injections in various regions can pose obstacles for manufacturers. To succeed, companies must focus on research and development to offer innovative and reliable glucagon injection solutions, collaborate with healthcare providers to promote awareness and training, and address the challenges to meet the increasing demand for effective and life-saving emergency treatments for hypoglycemia.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Glucagon Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Novo Nordisk
Eli Lilly
Fresenius Kabi
Torrent Labs
Amphastar Pharmaceuticals
Xeris Pharmaceuticals
Segment by Type
Vials
Prefilled
Hospital
Pharmacy
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Glucagon Injection report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Glucagon Injection market is projected to reach US$ 870.2 million in 2029, increasing from US$ 575 million in 2022, with the CAGR of 6.1% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Glucagon Injection market research.
The Glucagon injection market is driven by the rising prevalence of diabetes and hypoglycemia, and the growing awareness of the importance of emergency treatment for severe low blood sugar episodes. Glucagon injections are life-saving emergency medications used to rapidly raise blood sugar levels in individuals experiencing severe hypoglycemia. The rise in the global diabetic population and the need for effective management of insulin-related conditions contribute to market growth as glucagon injections offer a crucial solution in emergency situations. Moreover, advancements in device design and the development of user-friendly glucagon delivery systems have improved the accessibility and ease of administration. However, the market also faces challenges, including the need for patient education on proper administration and storage of glucagon injections, and the complexity of the regulatory landscape for medical emergency medications. Additionally, addressing affordability and expanding access to glucagon injections in various regions can pose obstacles for manufacturers. To succeed, companies must focus on research and development to offer innovative and reliable glucagon injection solutions, collaborate with healthcare providers to promote awareness and training, and address the challenges to meet the increasing demand for effective and life-saving emergency treatments for hypoglycemia.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Glucagon Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novo Nordisk
Eli Lilly
Fresenius Kabi
Torrent Labs
Amphastar Pharmaceuticals
Xeris Pharmaceuticals
Segment by Type
Vials
Prefilled
Segment by Application
Hospital
Pharmacy
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Glucagon Injection report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices